Golden
CRISPR-Cas13

CRISPR-Cas13

A nucleic acid editing technology that targets RNA, analogous to the CRISPR-Cas9 system

All edits

Edits on 14 Nov 2018
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 14 Nov 2018 6:49 pm
Edits made to:
Related Topics (+1 topics)

Related Topics

Edits on 6 Nov 2018
Meredith Hanel
Meredith Hanel edited on 6 Nov 2018 2:35 am
Edits made to:
Related Topics (+2 topics)
Meredith Hanel
Meredith Hanel edited on 6 Nov 2018 2:34 am
Edits made to:
Categories (-3 topics)
Related Topics (+2 topics)
Edits on 29 Oct 2018
Meredith Hanel
Meredith Hanel edited on 29 Oct 2018 5:16 pm
Edits made to:
Description (+11/-11 characters)
Topic thumbnail

CRISPR-Cas13

A nucleic acid editing technology that targets RNA, analogous to the CRISPR-Cas9CRISPR-Cas9 system

Meredith Hanel
Meredith Hanel edited on 29 Oct 2018 4:14 pm
Edits made to:
Article (+12 characters)

Article

CRISPR-Cas13 is an RNA targeting and editing system based on the bacterial immune system that protects them from viruses. Cas13, previously known as C2c2, is the effector protein that targets and cleaves invading nucleic acids from viruses in type VI CRISPR-Cas systems. The CRISPR-Cas13 system is analogous to the CRISPR-Cas9 system. However, unlike Cas-9 which targets DNA, Cas-13 targets and cleaves single stranded RNA. Cas-13 was first discovered in L. shahii, a species of the Leptotrichia bacteria while researchers were looking for previously unidentified CRISPR systems. Members of Cas13, Cas13a and Cas13b are being developed for therapeutic gene correction at the RNA level and detection of viral pathogens.

Meredith Hanel
Meredith Hanel edited on 29 Oct 2018 4:14 pm
Edits made to:
Article (-5 characters)

Article

CRISPR-Cas13 is an RNA targeting and editing system based on the bacterial immune system that protects them from viruses. Cas13, previously known as C2c2, is the effector protein that targets and cleaves invading nucleic acids from viruses in type VI CRISPR-Cas systems. The CRISPR-Cas13 system is analogous to the CRISPR-Cas9 system. However, unlike Cas-9 which targets DNA, Cas-13 targets and cleaves single stranded RNA. Cas-13 was first discovered in L. shahii, a species of the Leptotrichia bacteria while researchers were looking for previously unidentified CRISPR systems. Members of Cas13, Cas13a and Cas13b have are being developed for gene correction at the RNA level and detection of viral pathogens.

Meredith Hanel
Meredith Hanel edited on 29 Oct 2018 4:13 pm
Edits made to:
Description (+11/-10 characters)
Article (+131/-2481 characters)
Topic thumbnail

CRISPR-Cas13

A nucleic acid editing technology focusingthat ontargets RNA, analogous to the CRISPR-Cas9 system

Article

CRISPR-Cas13 is an RNA targeting and editing system based on the bacterial immune system that protects them from viruses. Cas13, previously known as C2c2, is the effector protein that targets and cleaves invading nucleic acids from viruses in type VI CRISPR-Cas systems. The CRISPR-Cas13 system is analogous to the CRISPR-Cas9 system. However, unlike Cas-9 which targets DNA, Cas-13 targets and cleaves single stranded RNA. Cas-13 was first discovered in L. shahii, a species of the Leptotrichia bacteria while researchers were looking for previously unidentified CRISPR systems. Members of Cas13, Cas13a and Cas13b have are being developed for gene correction at the RNA level and detection of viral pathogens.

...

Feng Zhang at the Broad Institute at MIT and Harvard was part of the team that originally showed that CRISPR-Cas9 gene editing could function in human cells . His lab has lead the developent of CRIPR-Cas13 as a biological research tool and for biomedical applications. Zhang’s lab has shown that one member of the Cas13 enzyme family, Cas13a from Leptotrichia wadei, can be used to knockdown mammalian and plant cell RNA to reduce the expression of the target gene . Zhang’s lab also engineered an inactive form of Cas13a with GFP that binds RNA without cutting which can make RNA of interest trackable in live cells .

...

The RNA Editing for Programmable A to I Replacement (REPAIR) system based on CRISPR-Cas13 was developed by Zhang’s lab to edit RNA transcripts with pathogenic mutations . Here, the Cas13b ortholog from the bacterium Prevotella sp. P5–125 was engineered to not cleave RNA (dCas13b) and fused to an adensosine deaminase enzyme which changes A to I in targeted spot on an RNA transcript as determined by the user supplied guide RNA. Zhang’s team used REPAIR to correct RNA transcripts in cell lines from patients with mutations causing Fanconi anemia and X-linked Nephrogenic diabetes insipidus. The REPAIR system is engineered for viral delivery into cells. There are less sequence constraints for CRISPR-Cas13 RNA editing than for CRISPR-Cas9 DNA editing, making it more flexible. However since the REPAIR system targets RNA not DNA, effects are temporary. Zheng's group suggests it would be suitable to treat diseases with acute phases like inflammation or modify proteins in the disease pathway to slow disease progression.

...

Zhang and collaborators developed a nucleic acid detection system based on Cas13a, called SHERLOCK (Specific High Sensitivity Enzymatic Reporter UnLOCKing) that can detect viruses, distinguish pathogenic bacteria, genotype human DNA and cell-free tumor DNA mutations . DNA or RNA is amplified with recombinase polymerase and converted to RNA with T7 RNA polymerase. When Cas13a recognizes its RNA target it cleaves non-target RNA nearby. SHERLOCK includes a reporter RNA that fluoresces when cleaved to show target virus sequence has been detected. Zhang collaborated with virology researcher Pardis Sabeti, also at the Broad Institute at MIT and Harvard to demonstrate the use of SHERLOCK to detect Zika virus and dengue virus, instrument-free, in patient body fluids (urine and saliva) at concentrations of 1 copy per microliter .





Edits on 7 Sep 2018
Jude Gomila
Jude Gomila edited on 7 Sep 2018 12:29 am
Edits made to:
Categories (+1 topics)

Categories

Edits on 21 Aug 2018
Meredith Hanel
Meredith Hanel edited on 21 Aug 2018 7:45 pm
Edits made to:
Categories (+1 topics)

Categories

Edits on 7 Aug 2018
Golden AI"Linkify text links in standard tables"
Golden AI edited on 7 Aug 2018 11:09 pm
Edits made to:
Further reading (+258/-258 characters)

Further reading

Author
Title
Link
Type

Abudayyeh et al.

C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector

Academic paper

Alex Philippidis

New Version of CRISPR, Developed by Feng Zhang–Led Team, Can Target and Edit RNA

Academic paper

David B. T. Cox

RNA editing with CRISPR-Cas13

Academic paper

Edits on 30 Jul 2018
Michael Mangus
Michael Mangus edited on 30 Jul 2018 6:31 pm
Edits made to:
Article (+15/-15 characters)

Article

Feng Zhang at the Broad InstituteBroad Institute at MIT and Harvard was part of the team that originally showed that CRISPR-Cas9 gene editing could function in human cells . His lab has lead the developent of CRIPR-Cas13 as a biological research tool and for biomedical applications. Zhang’s lab has shown that one member of the Cas13 enzyme family, Cas13a from Leptotrichia wadei, can be used to knockdown mammalian and plant cell RNA to reduce the expression of the target gene . Zhang’s lab also engineered an inactive form of Cas13a with GFP that binds RNA without cutting which can make RNA of interest trackable in live cells .

Michael Mangus
Michael Mangus edited on 30 Jul 2018 6:31 pm
Edits made to:
Article (+13/-13 characters)

Article

CRISPR-Cas13 is an RNA targeting and editing system based on the bacterial immune systemimmune system that protects them from viruses. Cas13, previously known as C2c2, is the effector protein that targets and cleaves invading nucleic acids from viruses in type VI CRISPR-Cas systems. The CRISPR-Cas13 system is analogous to the CRISPR-Cas9 system. However, unlike Cas-9 which targets DNA, Cas-13 targets and cleaves single stranded RNA. Cas-13 was first discovered in L. shahii, a species of the Leptotrichia bacteria while researchers were looking for previously unidentified CRISPR systems.

Michael Mangus
Michael Mangus edited on 30 Jul 2018 6:31 pm
Edits made to:
Article (+14/-14 characters)

Article

The RNA Editing for Programmable A to I Replacement (REPAIR) system based on CRISPR-Cas13 was developed by Zhang’s lab to edit RNA transcripts with pathogenic mutations . Here, the Cas13b ortholog from the bacterium Prevotella sp. P5–125 was engineered to not cleave RNA (dCas13b) and fused to an adensosine deaminase enzyme which changes A to I in targeted spot on an RNA transcript as determined by the user supplied guide RNA. Zhang’s team used REPAIR to correct RNA transcripts in cell lines from patients with mutations causing Fanconi anemiaFanconi anemia and X-linked Nephrogenic diabetes insipidus. The REPAIR system is engineered for viral delivery into cells. There are less sequence constraints for CRISPR-Cas13 RNA editing than for CRISPR-Cas9 DNA editing, making it more flexible. However since the REPAIR system targets RNA not DNA, effects are temporary. Zheng's group suggests it would be suitable to treat diseases with acute phases like inflammation or modify proteins in the disease pathway to slow disease progression.

Michael Mangus
Michael Mangus edited on 30 Jul 2018 6:31 pm
Edits made to:
Article (+3/-3 characters)

Article

Feng Zhang at the Broad Institute at MITMIT and Harvard was part of the team that originally showed that CRISPR-Cas9 gene editing could function in human cells . His lab has lead the developent of CRIPR-Cas13 as a biological research tool and for biomedical applications. Zhang’s lab has shown that one member of the Cas13 enzyme family, Cas13a from Leptotrichia wadei, can be used to knockdown mammalian and plant cell RNA to reduce the expression of the target gene . Zhang’s lab also engineered an inactive form of Cas13a with GFP that binds RNA without cutting which can make RNA of interest trackable in live cells .

Michael Mangus
Michael Mangus edited on 30 Jul 2018 6:31 pm
Edits made to:
Article (+13/-13 characters)

Article

Zhang and collaborators developed a nucleic acid detection system based on Cas13a, called SHERLOCK (Specific High Sensitivity Enzymatic Reporter UnLOCKing) that can detect viruses, distinguish pathogenic bacteria, genotype human DNA and cell-free tumor DNA mutations . DNA or RNA is amplified with recombinase polymerase and converted to RNA with T7 RNA polymerase. When Cas13a recognizes its RNA target it cleaves non-target RNA nearby. SHERLOCK includes a reporter RNA that fluoresces when cleaved to show target virus sequence has been detected. Zhang collaborated with virology researcher Pardis SabetiPardis Sabeti, also at the Broad Institute at MIT and Harvard to demonstrate the use of SHERLOCK to detect Zika virus and dengue virus, instrument-free, in patient body fluids (urine and saliva) at concentrations of 1 copy per microliter .

Meredith Hanel
Meredith Hanel edited on 30 Jul 2018 6:21 pm
Edits made to:
People (+6 cells) (+99 characters)

People

Name
Role
Related Golden topics

Eugene Koonin

Primary Investigator



Feng Zhang

Primary Investigator



Pardis C. Sabeti

Primary Investigator



Meredith Hanel
Meredith Hanel edited on 30 Jul 2018 6:16 pm
Edits made to:
Article (+2873/-320 characters)
People (-1 cells) (-10 characters)
Further reading (+4 cells) (+138 characters)

Article

CRISPR-Cas13 is alsoan RNA targeting and editing system based on the bacterial immune system that protects them from viruses. Cas13, previously known as C2c2, is the effector protein that targets and cleaves invading nucleic acids from viruses in type VI CRISPR-Cas Type VI and used to be known as C2c2systems. ItThe CRISPR-Cas13 system is analogous to the CRISPR-Cas9 system. However, unlike Cas-9 which targets DNA, Cas-13 targets and cleaves single stranded RNA. One memberCas-13 ofwas thefirst Cas13discovered enzymein family,L. Cas-13ashahii,, can bea usedspecies toof knockdownthe mammalianLeptotrichia cellbacteria RNAwhile andresearchers reducewere thelooking expressionfor ofpreviously anunidentified organismsCRISPR genessystems.

...

Cas-13 was first discovered in L. shahii, a species of the Leptotrichia bacteria while researchers were looking for previously unidentified CRISPR systems.

Feng Zhang at the Broad Institute at MIT and Harvard was part of the team that originally showed that CRISPR-Cas9 gene editing could function in human cells . His lab has lead the developent of CRIPR-Cas13 as a biological research tool and for biomedical applications. Zhang’s lab has shown that one member of the Cas13 enzyme family, Cas13a from Leptotrichia wadei, can be used to knockdown mammalian and plant cell RNA to reduce the expression of the target gene . Zhang’s lab also engineered an inactive form of Cas13a with GFP that binds RNA without cutting which can make RNA of interest trackable in live cells .



The RNA Editing for Programmable A to I Replacement (REPAIR) system based on CRISPR-Cas13 was developed by Zhang’s lab to edit RNA transcripts with pathogenic mutations . Here, the Cas13b ortholog from the bacterium Prevotella sp. P5–125 was engineered to not cleave RNA (dCas13b) and fused to an adensosine deaminase enzyme which changes A to I in targeted spot on an RNA transcript as determined by the user supplied guide RNA. Zhang’s team used REPAIR to correct RNA transcripts in cell lines from patients with mutations causing Fanconi anemia and X-linked Nephrogenic diabetes insipidus. The REPAIR system is engineered for viral delivery into cells. There are less sequence constraints for CRISPR-Cas13 RNA editing than for CRISPR-Cas9 DNA editing, making it more flexible. However since the REPAIR system targets RNA not DNA, effects are temporary. Zheng's group suggests it would be suitable to treat diseases with acute phases like inflammation or modify proteins in the disease pathway to slow disease progression.



Zhang and collaborators developed a nucleic acid detection system based on Cas13a, called SHERLOCK (Specific High Sensitivity Enzymatic Reporter UnLOCKing) that can detect viruses, distinguish pathogenic bacteria, genotype human DNA and cell-free tumor DNA mutations . DNA or RNA is amplified with recombinase polymerase and converted to RNA with T7 RNA polymerase. When Cas13a recognizes its RNA target it cleaves non-target RNA nearby. SHERLOCK includes a reporter RNA that fluoresces when cleaved to show target virus sequence has been detected. Zhang collaborated with virology researcher Pardis Sabeti, also at the Broad Institute at MIT and Harvard to demonstrate the use of SHERLOCK to detect Zika virus and dengue virus, instrument-free, in patient body fluids (urine and saliva) at concentrations of 1 copy per microliter .







People

Name
Role
Related Golden topics

Feng Zhang





Further reading

Author
Title
Link
Type

Zahir Ali

CRISPR/Cas13 as a Tool for RNA Interference

Academic paper

Edits on 18 Jul 2018
Jude Gomila
Jude Gomila edited on 18 Jul 2018 1:08 am
Edits made to:
Article (+3/-3 characters)

Article

CRISPR-Cas13 is also known as CRISPR-Cas Type VI and used to be known as C2c2. It is analogous to the CRISPR-Cas9 system. However, unlike Cas-9 which targets DNA, Cas-13 targets and cleaves single stranded RNARNA. One member of the Cas13 enzyme family, Cas-13a, can be used to knockdown mammalian cell RNA and reduce the expression of an organisms genes.

Jude Gomila
Jude Gomila edited on 18 Jul 2018 1:08 am
Edits made to:
Article (+3/-3 characters)

Article

CRISPR-Cas13 is also known as CRISPR-Cas Type VI and used to be known as C2c2. It is analogous to the CRISPR-Cas9 system. However, unlike Cas-9 which targets DNADNA, Cas-13 targets and cleaves single stranded RNA. One member of the Cas13 enzyme family, Cas-13a, can be used to knockdown mammalian cell RNA and reduce the expression of an organisms genes.

Edits on 5 Jun 2018
Tianchang He
Tianchang He edited on 5 Jun 2018 8:46 pm
Edits made to:
Further reading (+15/-15 characters)

Further reading

Author
Title
Link
Type

Abudayyeh et al.

C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector

Academic Paperpaper

Alex Philippidis

New Version of CRISPR, Developed by Feng Zhang–Led Team, Can Target and Edit RNA

Academic Paperpaper

David B. T. Cox

RNA editing with CRISPR-Cas13

Academic Paperpaper